Physician profile
Lisa Harding
NPI 1629427778
$607,565.31
in general payments reported to CMS, 2019-2025
9 companies · $120K in 2025
The $120K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97K · 2022: $136K · 2023: $151K · 2024: $104K · 2025: $120K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $230K · Consulting Fee: $86K · Travel and Lodging: $51K · Food and Beverage: $6,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $230,293.00 |
| Consulting Fee | $86,067.08 |
| Travel and Lodging | $51,499.19 |
| Food and Beverage | $6,876.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $528,874.29 | 2021-2025 | Spravato, Invega Sustenna, Invega |
| Janssen Scientific Affairs, LLC | $54,679.39 | 2021-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $12,407.91 | 2024-2025 | |
| Eli Lilly and Company | $9,671.57 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,244.17 | 2024-2025 | |
| Axsome Therapeutics, INC. | $545.41 | 2023-2025 | Auvelity |
| Sage Therapeutics, LLC | $61.80 | 2023 | |
| Acadia Pharmaceuticals INC | $53.25 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $27.52 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.